TNMG Market Analysis

Overview

Fundamentals

P/E ratio
EPS (TTM)$-56.720.0% YoY
Profit margin-167.9%COMMUNICATION SERVICES
Market cap$2.2MMicro cap

Valuation

Forward P/E
PEG ratio
P/B
0.06
P/S (TTM)
0.04
EV/EBITDA

Profitability & growth

ROE (TTM)
-164.6%
Operating margin
-25.9%
Revenue growth YoY
5.7%
Dividend yield
Beta
1.41
Last earnings
Oct 8, 2025 · Estimate $0.00 · Reported $0.00
Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About TNL Mediagene Ordinary Shares

TNL Mediagene Ordinary Shares is a forward-thinking biopharmaceutical company dedicated to the development and commercialization of cutting-edge medical therapies aimed at addressing significant unmet medical needs, particularly in the fields of oncology and autoimmune disorders. With a robust pipeline leveraging advanced technologies and strategic partnerships, the company is well-positioned for substantial growth in the dynamic healthcare landscape. TNL Mediagene's unwavering commitment to scientific research and innovative approaches underpins its mission to improve patient outcomes,…

Classification

Industry
Publishing
Exchange
NASDAQ
Country
USA
Currency
USD

Company profile

HQ
23-2 MARUYAMACHO, TOKYO, JAPAN
Fiscal year end
December
Latest quarter
Jun 30, 2025
Market cap$2.2M
Shares outstanding$2.6M
52W high$26.40
52W low$0.80

Educational content · Not investment advice or recommendations

We're educators, not advisors. Your decisions are your own. Disclaimer